Enhertu Is First ADC Approved For Tumor-Agnostic Indication

 
• By Jessica Merrill
  
rainbow
Enhertu is approved for use across a broad spectrum of HER2-positive tumors • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip